Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
mouse bone marrow macrophages
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "mouse bone marrow macrophages" in MCE Product Catalog:
3
3 Cited Publications
Research Areas:
RO5256390 is an orally effective trace amine associated receptor 1 (TAAR1) agonist. RO5256390 exhibits pro-cognitive and antidepressant-like properties in rodent and primate models, showing similar brain activation patterns to Olanzapine (HY-14541). RO5256390 blocks compulsive overeating behavior in rats. RO5256390 can inhibit ATP (HY-B2176)-induced TNF secretion in mouse bone marrow-derived macrophages .
2
2 Cited Publications
Cat. No.: HY-W008634
CAS No.: 56741-95-8
Synonyms: U-54461; U-54461S; PNU-54461
Target:
Research Areas:
Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis .
Target:
Research Areas:
PKR-IN-C51 is an ATP-competitive protein kinase R (PKR) inhibitor with a human IC50 of 9 μM and a human Ki of 3.4 μM. PKR-IN-C51 blocks the activation of PKR, inhibits intracellular PKR activation in primary mouse macrophages, and shows no obvious cytotoxicity. PKR-IN-C51 can be used in studies related to the regulation of PKR-mediated signaling pathways .
Target:
Research Areas:
TLR7 agonist 4 is a TLR7 agonist with pro-inflammatory cytokine-stimulating activity. TLR7 agonist 4 modulates TLR7 activity to stimulate the production of pro-inflammatory cytokines. TLR7 agonist 4 stimulates mouse bone marrow-derived macrophages to produce the pro-inflammatory cytokine TNFα. TLR7 agonist 4 can be conjugated with antibodies to form conjugates. TLR7 agonist 4 is applicable to cancer research .
Target:
Research Areas:
SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .
Cat. No.: HY-173070
CAS No.: 2275612-76-3
Research Areas:
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .
Cat. No.: HY-175645
CAS No.: 2994637-53-3
Research Areas:
NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC50 = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC50 of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .
Cat. No.: HY-W615446
CAS No.: 158890-32-5
Research Areas:
GSTO1-IN-3 is a potent GSTO1-1 inhibitor with an IC50 of 0.11 μM, and shows selectivity over GSTO2-2, GSTA1-1 and GSTP1-1 (IC50 > 100 μM). GSTO1-IN-3 enhances the cytotoxicity of Cisplatin (HY-17394) against human breast cancer cells. GSTO1-IN-3 inhibits IL-1β release in mouse bone marrow-derived macrophage (BMDM) cells. GSTO1-IN-3 attenuates inflammation in mice. GSTO1-IN-3 can be used for breast cancer and inflammation research .
Cat. No.: HY-P11413
CAS No.: 139446-70-1
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Cat. No.: HY-168089
Target:
Research Areas:
NLRP3-IN-49 (compound Z48) is a potent and specific NLRP3 inhibitor (IC50=0.26 μM in THP-1 cells, IC50=0.21 μM in mouse bone marrow macrophages). NLRP3-IN-49 can directly bind to NLRP3 protein (Kd=1.05 μM), effectively preventing the assembly and activation of NLRP3 inflammasome, thereby exhibiting anti-inflammatory properties. NLRP3-IN-49 can be used in the study of inflammatory bowel disease .
Cat. No.: HY-N11494
CAS No.: 345641-00-1
Target:
Cat. No.: HY-152940
CAS No.: 887907-50-8
Synonyms: C24:1 β-glucosylceramide
Research Areas:
βGlcCer is a glycosphingolipid. βGlcCer directly increases the development and PKCα and PKCδ activation in mouse bone marrow-derived DCs (BMDCs) . β-GlcCer accumulating in Gaucher disease activates microglia through macrophage-inducible C-type lectin (Mincle) to induce phagocytosis of living neurons, which exacerbates Gaucher symptoms .
Cat. No.: HY-102065R
CAS No.: 19395-87-0
Research Areas:
SC-19220 (Standard) is the analytical standard of SC-19220 (HY-102065). This product is intended for research and analytical applications. SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .
Cat. No.: HY-182757
CAS No.: 2812381-74-9
Research Areas:
Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
